Get the Stockscreener App
329.89
3.07%
-10.44
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Amgen Inc stock is traded at $329.89, with a volume of 2.89M.
It is down -3.07% in the last 24 hours and up +3.14% over the past month.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
See More
Previous Close:
$340.32
Open:
$340.36
24h Volume:
2.89M
Relative Volume:
1.11
Market Cap:
$177.64B
Revenue:
$35.89B
Net Income/Loss:
$7.01B
P/E Ratio:
25.50
EPS:
12.9352
Net Cash Flow:
$11.54B
1W Performance:
-4.51%
1M Performance:
+3.14%
6M Performance:
+14.90%
1Y Performance:
+20.25%
1-Day Range:
$328.63
$340.88
1-Week Range:
$328.63
$346.38
52-Week Range:
$253.30
$346.38
Amgen Inc Stock (AMGN) Company Profile
Name
Amgen Inc
Sector
Industry
Phone
(805)447-1000
Address
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
329.89 | 183.17B | 35.89B | 7.01B | 11.54B | 12.94 |
|
LLY
Lilly Eli Co
|
1,010.31 | 907.99B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
201.93 | 487.83B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
226.08 | 404.22B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
132.16 | 254.11B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
99.72 | 250.41B | 63.90B | 19.05B | 13.05B | 7.5596 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Resumed | Truist | Hold |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Sep-03-25 | Resumed | Raymond James | Mkt Perform |
| May-20-25 | Resumed | Guggenheim | Neutral |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-14-24 | Initiated | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-14-24 | Downgrade | Truist | Buy → Hold |
| Sep-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-03-24 | Upgrade | Barclays | Underweight → Equal Weight |
| May-03-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Mar-28-24 | Resumed | Raymond James | Mkt Perform |
| Feb-07-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-21-23 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-19-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-12-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Upgrade | Truist | Hold → Buy |
| Oct-20-23 | Resumed | JP Morgan | Neutral |
| Oct-17-23 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-11-23 | Resumed | BofA Securities | Neutral |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Apr-24-23 | Reiterated | Oppenheimer | Outperform |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-13-23 | Reiterated | Truist | Buy |
| Nov-18-22 | Initiated | Credit Suisse | Underperform |
| Oct-31-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Oct-11-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-09-22 | Reiterated | Barclays | Equal Weight |
| Feb-09-22 | Reiterated | Jefferies | Buy |
| Feb-09-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Feb-09-22 | Reiterated | Oppenheimer | Outperform |
| Feb-09-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Sep-23-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-29-20 | Initiated | Daiwa Securities | Buy |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-26-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-12-20 | Upgrade | Truist | Hold → Buy |
| Oct-09-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Oct-09-20 | Downgrade | Truist | Buy → Hold |
| Oct-08-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-15-20 | Resumed | Guggenheim | Neutral |
| Mar-31-20 | Initiated | Wolfe Research | Peer Perform |
| Mar-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-05-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-31-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jan-21-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-24-19 | Initiated | Raymond James | Mkt Perform |
| Dec-17-19 | Resumed | Morgan Stanley | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-05-19 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-19-19 | Downgrade | Mizuho | Buy → Neutral |
| May-23-19 | Upgrade | Citigroup | Neutral → Buy |
View All
Amgen Inc Stock (AMGN) Latest News
A Closer Look at Amgen (AMGN) Valuation After Its 12-Month 28% Share Price Gain - simplywall.st
Erste Group upgrades Amgen stock rating to Buy from Hold on obesity drug - Investing.com
Amgen (NASDAQ:AMGN) Rating Increased to Buy at Erste Group Bank - MarketBeat
Amgen Named Official Biotech Partner by Los Angeles Sports & Entertainment Commission (LASEC) Ahead of FIFA World Cup 2026 - Amgen
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock - Yahoo Finance
Tema Etfs LLC Has $3.62 Million Stock Holdings in Amgen Inc. $AMGN - MarketBeat
What makes Amgen Inc. (AMG0) stock appealing to growth investorsMarket Performance Recap & Smart Money Movement Alerts - Newser
Is Amgen Inc. (AMG0) stock overpriced at current multiplesEarnings Risk Report & Long-Term Investment Growth Plans - Newser
First Trust Advisors LP Sells 21,347 Shares of Amgen Inc. $AMGN - MarketBeat
Beutel Goodman & Co Ltd. Raises Position in Amgen Inc. $AMGN - MarketBeat
Baird Financial Group Inc. Cuts Position in Amgen Inc. $AMGN - MarketBeat
Arrowstreet Capital Limited Partnership Makes New Investment in Amgen Inc. $AMGN - MarketBeat
Why Is Amgen (AMGN) Up 8% Since Last Earnings Report? - Yahoo Finance
Pharmaceutical Marketing Industry Trends and Emerging Opportunities 2025-2032 Featuring Syneos Health, McCann Health, Amgen, AXPIRA, Pfizer and MoreResearchAndMarkets.com - Markets Financial Content
Amgen (NASDAQ:AMGN) Shareholders Have Earned a 12% CAGR Over the Last Five Years - 富途牛牛
Amgen: Stagnation And The IRS Are Coming (NASDAQ:AMGN) - Seeking Alpha
Does Amgen Stock Lead the Pack? - Trefis
3 Top ETFs I Plan to Pile Into in December to Boost My Passive Income in 2026 - The Motley Fool
EverSource Wealth Advisors LLC Cuts Position in Amgen Inc. $AMGN - MarketBeat
Guggenheim Capital LLC Boosts Stake in Amgen Inc. $AMGN - MarketBeat
Will Strong Q3 Beat And Pipeline Updates Change Amgen's (AMGN) Future Earnings Narrative? - simplywall.st
BMO Capital Maintains Amgen (AMGN) Outperform Recommendation - Nasdaq
Amgen (NASDAQ:AMGN) Reaches New 12-Month HighStill a Buy? - MarketBeat
Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza - Benzinga
Key facts: Amgen reports strong growth; BMO raises price target to $372 - TradingView
Amgen stock hits 52-week high at $345.95 By Investing.com - Investing.com Nigeria
Amgen stock hits 52-week high at $345.95 - Investing.com
Amgen (AMGN) Stock Hits New 52‑Week High as Obesity Drug Bets and Analyst Upgrades Fuel 2025 Rally - ts2.tech
Biocon and Amgen Reach Deal to Commercialise Biosimilars in Europe - Chemical Industry Digest
BMO Capital Raises Price Target for Amgen (AMGN) to $372, Mainta - GuruFocus
BMO Capital Adjusts Price Target on Amgen to $372 From $335, Maintains Outperform Rating - marketscreener.com
Invesco Ltd. Buys 339,755 Shares of Amgen Inc. $AMGN - MarketBeat
UPC Court Of Appeal Overturns Revocation Of Amgen's PCSK9 Antibody Patent And Clarifies The UPC's Inventive Step Approach (Amgen v Sanofi And Regeneron) - MarketScreener
Goldman Sachs Maintains Price Target on Amgen (AMGN) Before Key Trial Readouts - Insider Monkey
Extensive-Stage Small Cell Lung Cancer Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | EpicentRx, Ipsen, Bristol-Myers Squibb, Xcovery Holding Company, Amgen - Barchart.com
M&T Bank Corp Sells 61,385 Shares of Amgen Inc. $AMGN - MarketBeat
Bio Meets Tech: How Amgen is Designing the Medicines of Tomorrow - Amgen
OMERS ADMINISTRATION Corp Cuts Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Biocon Biologics settles with Amgen to launch Denosumab Biosimilars in Europe, rest of the world - Zee Business
Biocon Biologics settles with Amgen Inc to commercialise biosimilars in Europe - Daily Excelsior
How the Story Behind Amgen Is Shifting After Pipeline and Guidance Updates - Yahoo Finance
Amgen Inc. $AMGN Shares Sold by Fisher Asset Management LLC - MarketBeat
Edgestream Partners L.P. Buys 12,318 Shares of Amgen Inc. $AMGN - MarketBeat
Beacon Pointe Advisors LLC Sells 4,768 Shares of Amgen Inc. $AMGN - MarketBeat
Is Amgen Inc. (AMG) stock supported by strong fundamentals2025 Major Catalysts & Reliable Entry Point Trade Alerts - Newser
Amgen (AMGN): Company Profile, Stock Price, News, Rankings - Fortune
How strong is Amgen Inc. (AMG0) stock earnings growthJuly 2025 Short Interest & Risk Controlled Swing Alerts - Newser
Biocon Biologics reaches settlement with Amgen for Denosumab biosimilars commercialisation - Express Pharma
Biocon Biologics announces settlement agreement with Amgen Inc. - Business Standard
Amgen Stock (AMGN) Today: Q3 2025 Earnings Beat, MariTide Obesity Drug Outlook and 2030 Price Forecast - ts2.tech
Is the Market Bullish or Bearish on Amgen Inc? - Benzinga
Amgen Inc Stock (AMGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Amgen Inc Stock (AMGN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grygiel Nancy A. | SVP & CCO |
Nov 20 '25 |
Sale |
337.26 |
3,139 |
1,058,667 |
7,225 |
0.98%
1.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):